CN104768967B - 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 - Google Patents

细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 Download PDF

Info

Publication number
CN104768967B
CN104768967B CN201380057722.4A CN201380057722A CN104768967B CN 104768967 B CN104768967 B CN 104768967B CN 201380057722 A CN201380057722 A CN 201380057722A CN 104768967 B CN104768967 B CN 104768967B
Authority
CN
China
Prior art keywords
peptide
cell
active constituent
seq
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380057722.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104768967A (zh
Inventor
金商在
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jim Vickers & Kyle Co ltd
GemVax and Kael Co Ltd
Original Assignee
Jim Vickers & Kyle Co ltd
GemVax and Kael Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jim Vickers & Kyle Co ltd, GemVax and Kael Co Ltd filed Critical Jim Vickers & Kyle Co ltd
Priority to CN201910048425.2A priority Critical patent/CN110028554B/zh
Priority to CN201910049089.3A priority patent/CN110064056B/zh
Publication of CN104768967A publication Critical patent/CN104768967A/zh
Application granted granted Critical
Publication of CN104768967B publication Critical patent/CN104768967B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
CN201380057722.4A 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 Active CN104768967B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910048425.2A CN110028554B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201910049089.3A CN110064056B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR10-2012-0104144 2012-09-19
KR20120104144 2012-09-19
KR10-2012-0109216 2012-09-28
KR20120109216 2012-09-28
KR10-2013-0017046 2013-02-18
KR20130017046 2013-02-18
KR20130017169 2013-02-18
KR10-2013-0017169 2013-02-18
PCT/KR2013/008445 WO2014046481A1 (ko) 2012-09-19 2013-09-17 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910049089.3A Division CN110064056B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201910048425.2A Division CN110028554B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Publications (2)

Publication Number Publication Date
CN104768967A CN104768967A (zh) 2015-07-08
CN104768967B true CN104768967B (zh) 2019-02-15

Family

ID=50341702

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380057722.4A Active CN104768967B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201910048425.2A Active CN110028554B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201910049089.3A Active CN110064056B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910048425.2A Active CN110028554B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN201910049089.3A Active CN110064056B (zh) 2012-09-19 2013-09-17 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物

Country Status (8)

Country Link
US (1) US9631184B2 (enExample)
EP (1) EP2899199B1 (enExample)
JP (1) JP6510410B2 (enExample)
KR (1) KR102201430B1 (enExample)
CN (3) CN104768967B (enExample)
ES (1) ES2743919T3 (enExample)
TW (1) TWI598441B (enExample)
WO (1) WO2014046481A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
EP2875826B1 (en) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3736282B1 (en) 2012-09-19 2023-06-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899201B1 (en) 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
AU2014275610B2 (en) 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
EP3020724A4 (en) * 2013-07-12 2017-01-18 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
ES2773296T3 (es) 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
ES2908096T3 (es) 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
EP3305802B1 (en) 2015-05-26 2021-05-12 Gemvax & Kael Co., Ltd. Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20180064434A (ko) * 2015-11-03 2018-06-14 주식회사 젬백스앤카엘 신경세포 손실 예방 및 재생 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR101661912B1 (ko) 2016-01-29 2016-10-04 (주)넥스젠바이오텍 녹색형광단백질-인간 상피세포재생인자 융합단백질을 유효성분으로 포함하는 주름 개선 및 항노화 화장료 조성물
ES2949697T3 (es) 2016-04-07 2023-10-02 Gemvax & Kael Co Ltd Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20230181681A1 (en) * 2020-05-08 2023-06-15 Industry Academic Cooperation Foundation, Hallym University Peptide for suppressing coronavirus and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002581A1 (en) * 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
US20070190561A1 (en) * 1996-10-01 2007-08-16 Geron Corporation Segments of the Human Gene for Telomerase Reverse Transcriptase
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA199900355A1 (ru) * 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
US20030143228A1 (en) * 2001-10-29 2003-07-31 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
EP1968643A2 (en) 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
EP2837636B1 (en) 2007-01-29 2018-04-11 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
US8828403B2 (en) * 2008-06-16 2014-09-09 Mediolanum Farmaceutici S.P.A. Anti-tumor immunotherapy
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
AU2010250452B2 (en) 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) * 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
EP2899201B1 (en) 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP3736282B1 (en) 2012-09-19 2023-06-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR101778244B1 (ko) 2014-05-13 2017-09-26 한양대학교 산학협력단 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190561A1 (en) * 1996-10-01 2007-08-16 Geron Corporation Segments of the Human Gene for Telomerase Reverse Transcriptase
WO2000002581A1 (en) * 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cell-Penetrating Peptides and Peptide Nucleic Acid-Coupled MRI Contrast Agents: Evaluation of Cellular Delivery and Target Binding;Ritu Mishra et al.;《Bioconjugate Chem.》;20090929;第20卷;1860-1868 *
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial;Paal Fr. Brunsvig et al.;《Clinical Cancer Research》;20111101;第17卷(第21期);OF1-OF11 *

Also Published As

Publication number Publication date
CN110028554A (zh) 2019-07-19
TW201416448A (zh) 2014-05-01
EP2899199A4 (en) 2016-06-15
EP2899199A1 (en) 2015-07-29
CN104768967A (zh) 2015-07-08
JP6510410B2 (ja) 2019-05-08
CN110064056A (zh) 2019-07-30
KR102201430B1 (ko) 2021-01-12
CN110028554B (zh) 2023-04-07
TWI598441B (zh) 2017-09-11
EP2899199B1 (en) 2019-07-03
ES2743919T3 (es) 2020-02-21
WO2014046481A1 (ko) 2014-03-27
JP2015530404A (ja) 2015-10-15
US20160002613A1 (en) 2016-01-07
CN110064056B (zh) 2022-10-28
KR20150060763A (ko) 2015-06-03
US9631184B2 (en) 2017-04-25

Similar Documents

Publication Publication Date Title
CN104837859B (zh) 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CN104981478B (zh) 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
JP6272853B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP6510410B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
TWI616530B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: South Korea field wide area

Applicant after: Jane white Kell Co., Ltd.

Applicant after: Jin Shangzai

Address before: South Korea field wide area

Applicant before: Jim Vickers & Kyle Ltd

Applicant before: Jin Shangzai

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant